1 | Generic Medicines Industry Association (GMiA), Case study – amiloride, tabled at the Melbourne public hearing on 21 July 2011(PDF 77KB) |
2 | Chronic Illness Alliance, 'Prescription drug subsidies in Australia and New Zealand', Australian Prescriber, Vol 33, No. 1, February 2010, tabled at the Melbourne public hearing on 21 July 2011(PDF 880KB) |
3 | Allergan Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011, provided on 29 July 2011(PDF 86KB) |
4 | Mundipharma Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011 2011, provided on 5 August 2011(PDF 195KB) |
5 | Janssen-Cilag Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011(PDF 192KB) |
6 | Medicines Australia, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 8 August 2011(PDF 188KB) |
7 | Pharmaceutical Benefits Advisory Committee, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 9 August 2011(PDF 108KB) |
8 | Pfizer Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 10 August 2011(PDF 695KB) |
9 | Department of Health and Ageing, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 12 August 2011(PDF 75KB) |